

Zydus announces settlement with Upsher-Smith Laboratories, Inc. on Qudexy® XR (topiramate) extended-release capsules

Ahmedabad, January 13, 2017

Cadila Healthcare Limited, a global pharmaceuticals company, and its subsidiary Zydus Pharmaceuticals (USA) Inc., a leading generic pharmaceutical company in the United States, today announced that they have finalized an agreement with Upsher-Smith Laboratories, Inc. to settle all outstanding patent litigation related to Qudexy® XR (topiramate) extended-release capsules.

Under the terms of the agreement, Upsher-Smith grants Zydus a license to market Zydus' generic version of Qudexy® XR beginning on March 19, 2020, or earlier under certain circumstances. Other terms of the settlement were not disclosed.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 19,500 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.